Table 1 |
|
|
Patient demographics and baseline disease characteristics |
|
| Parameters |
n = 15 |
|
|
|
| Gender (female/male) |
13/2 |
| Age (years) |
49 (33–73) |
| Median years post-diagnosis |
2.9 (1–16) |
| Ocular symptoms |
15 (100%) |
| Schirmer-I test (mm) |
12 ± 12 |
| Oral symptoms |
15 (100%) |
| Unstimulated salivary flow (ml/minute) |
0.07 ± 0.13 |
| Moderate-to-severe fatigue |
13 (87%) |
| Fatigue VAS (mm) |
56 ± 22 |
| Focus score ≥ 1 |
12 (80%) |
| Anti-Ro antibodies |
12 (80%) |
| Anti-La antibodies |
11 (73%) |
| ESR (mm/hour) |
33 ± 15 |
| IgG (mg/dl) |
2,114 ± 934 |
|
|
|
|
ESR, erythrocyte sedimentation rate; Ig, immunoglobulin; VAS, visual analogue scale. |
|
|
Steinfeld et al. Arthritis Research & Therapy 2006 8:R129 doi:10.1186/ar2018 |
|
